[go: up one dir, main page]

WO2013087716A3 - Fgfr- binder -wirkstoff konjugate und ihre verwendung - Google Patents

Fgfr- binder -wirkstoff konjugate und ihre verwendung Download PDF

Info

Publication number
WO2013087716A3
WO2013087716A3 PCT/EP2012/075277 EP2012075277W WO2013087716A3 WO 2013087716 A3 WO2013087716 A3 WO 2013087716A3 EP 2012075277 W EP2012075277 W EP 2012075277W WO 2013087716 A3 WO2013087716 A3 WO 2013087716A3
Authority
WO
WIPO (PCT)
Prior art keywords
adcs
drug conjugates
antibody drug
illnesses
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/075277
Other languages
English (en)
French (fr)
Other versions
WO2013087716A2 (de
Inventor
Hans-Georg Lerchen
Stefanie Hammer
Axel Harrenga
Charlotte Christine Kopitz
Carl Friedrich Nising
Anette Sommer
Beatrix Stelte-Ludwig
Christoph Mahlert
Joachim Schuhmacher
Sven Golfier
Simone Greven
Sandra Bruder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Seagen Inc
Original Assignee
Bayer Pharma AG
Bayer Intellectual Property GmbH
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2859255A priority Critical patent/CA2859255A1/en
Priority to SG11201403085PA priority patent/SG11201403085PA/en
Priority to NZ625745A priority patent/NZ625745B2/en
Priority to RU2014128467A priority patent/RU2014128467A/ru
Priority to HK15101201.6A priority patent/HK1200714A1/xx
Priority to CN201280069771.5A priority patent/CN104254342A/zh
Priority to KR1020147019085A priority patent/KR20140114826A/ko
Priority to MX2014007121A priority patent/MX2014007121A/es
Priority to BR112014014763A priority patent/BR112014014763A8/pt
Priority to US14/364,203 priority patent/US20150023989A1/en
Priority to EP12808324.3A priority patent/EP2790731A2/de
Priority to AU2012351685A priority patent/AU2012351685A1/en
Application filed by Bayer Pharma AG, Bayer Intellectual Property GmbH, Seattle Genetics Inc filed Critical Bayer Pharma AG
Priority to JP2014546496A priority patent/JP2015505850A/ja
Publication of WO2013087716A2 publication Critical patent/WO2013087716A2/de
Publication of WO2013087716A3 publication Critical patent/WO2013087716A3/de
Priority to IL233050A priority patent/IL233050A0/en
Anticipated expiration legal-status Critical
Priority to ZA2014/05003A priority patent/ZA201405003B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die vorliegende Anmeldung betrifft neue, gegen das Target FGFR2 gerichtete Binder-Wirkstoff-Konjugate (ADCs) von N,N-Dialkylauristatinen, wirksamer Metabolite dieser ADCs, Verfahren zur Herstellung dieser ADCs, die Verwendung dieser ADCs zur Behandlung und/oder Prävention von Krankheiten sowie die Verwendung dieser ADCs zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere von hyperproliferativen und/oder angiogenen Erkrankungen wie beispielsweise Krebserkrankungen. Solche Behandlungen können als Monotherapie oder auch in Kombination mit anderen Arzneimitteln oder weiteren therapeutischen Maßnahmen erfolgen.
PCT/EP2012/075277 2011-12-14 2012-12-12 Neue binder-wirkstoff konjugate (adcs) und ihre verwendung Ceased WO2013087716A2 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SG11201403085PA SG11201403085PA (en) 2011-12-14 2012-12-12 Fgfr antibody drug conjugates (adcs) and the use thereof
NZ625745A NZ625745B2 (en) 2011-12-14 2012-12-12 FGFR antibody drug conjugates (ADCs) and the use thereof
RU2014128467A RU2014128467A (ru) 2011-12-14 2012-12-12 Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
HK15101201.6A HK1200714A1 (en) 2011-12-14 2012-12-12 Fgfr-binder-active agent conjugates
CN201280069771.5A CN104254342A (zh) 2011-12-14 2012-12-12 新抗体药物缀合物(adc)及其用途
KR1020147019085A KR20140114826A (ko) 2011-12-14 2012-12-12 Fgfr 항체 약물 콘주게이트 (adcs) 및 그의 용도
MX2014007121A MX2014007121A (es) 2011-12-14 2012-12-12 Nuevos conjugados de principio activo-ligante (adc) y su uso.
US14/364,203 US20150023989A1 (en) 2011-12-14 2012-12-12 New antibody drug conjugates (adcs) and the use thereof
BR112014014763A BR112014014763A8 (pt) 2011-12-14 2012-12-12 novos conjugados de anticorpo-medicamento (adcs) e uso dos mesmos
CA2859255A CA2859255A1 (en) 2011-12-14 2012-12-12 New antibody drug conjugates (adcs) and the use thereof
AU2012351685A AU2012351685A1 (en) 2011-12-14 2012-12-12 FGFR antibody drug conjugates (ADCs) and the use thereof
EP12808324.3A EP2790731A2 (de) 2011-12-14 2012-12-12 Fgfr-binder-wirkstoff konjugate und ihre verwendung
JP2014546496A JP2015505850A (ja) 2011-12-14 2012-12-12 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
IL233050A IL233050A0 (en) 2011-12-14 2014-06-10 New drug-antibody conjugates and their use
ZA2014/05003A ZA201405003B (en) 2011-12-14 2014-07-09 Fgfr antibody drug conjugates (adcs) and the use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11193617 2011-12-14
EP11193617.5 2011-12-14
EP12189467 2012-10-22
EP12189467.9 2012-10-22

Publications (2)

Publication Number Publication Date
WO2013087716A2 WO2013087716A2 (de) 2013-06-20
WO2013087716A3 true WO2013087716A3 (de) 2013-08-22

Family

ID=47458914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/075277 Ceased WO2013087716A2 (de) 2011-12-14 2012-12-12 Neue binder-wirkstoff konjugate (adcs) und ihre verwendung

Country Status (16)

Country Link
US (1) US20150023989A1 (de)
EP (1) EP2790731A2 (de)
JP (1) JP2015505850A (de)
KR (1) KR20140114826A (de)
CN (1) CN104254342A (de)
AR (1) AR089252A1 (de)
AU (1) AU2012351685A1 (de)
BR (1) BR112014014763A8 (de)
CA (1) CA2859255A1 (de)
HK (1) HK1200714A1 (de)
IL (1) IL233050A0 (de)
MX (1) MX2014007121A (de)
RU (1) RU2014128467A (de)
SG (1) SG11201403085PA (de)
WO (1) WO2013087716A2 (de)
ZA (1) ZA201405003B (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172937B2 (en) 2013-08-01 2019-01-08 Five Prime Therapeutics, Inc. Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies
US11091555B2 (en) 2017-05-16 2021-08-17 Five Prime Therapeutics, Inc. Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
US11447553B2 (en) 2015-11-23 2022-09-20 Five Prime Therapeutics, Inc. FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041805A1 (de) 2010-09-29 2012-04-05 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2914621B1 (de) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Neuartige ntrk1-fusionsmoleküle und verwendungen davon
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
SG11201601679TA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
IL320281A (en) 2013-12-25 2025-06-01 Daiichi Sankyo Co Ltd Anti-trop2 antibodies and methods for producing same
PH12020552271A1 (en) 2014-01-31 2022-05-02 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
EP3130608B1 (de) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2-antikörper)-arzneimittelkonjugat
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
KR20170117473A (ko) * 2015-02-15 2017-10-23 지앙수 헨그루이 메디슨 컴퍼니 리미티드 리간드-세포독성 약물 접합체, 이의 제조 방법 및 이의 적용
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3165237B1 (de) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antikörperwirkstoffkonjugat und herstellungsverfahren dafür
WO2017144015A1 (zh) * 2016-02-26 2017-08-31 江苏恒瑞医药股份有限公司 一种新毒素及其中间体的制备方法
CN110049779A (zh) 2016-12-12 2019-07-23 第一三共株式会社 抗体-药物缀合物和免疫检查点抑制剂的组合
EP3572428A4 (de) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited Anti-gpr20-antikörper und anti-gpr20-antikörper-arzneimittel-konjugat
WO2018140275A2 (en) * 2017-01-26 2018-08-02 Seattle Genetics, Inc. Novel auristatin derivatives and related antibody-drug conjugates (adcs) and methods of preparation thereof
TW202530271A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物及其用途
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
WO2019042447A1 (zh) * 2017-09-04 2019-03-07 江苏恒瑞医药股份有限公司 一种新毒素及其中间体的制备方法
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
ES2952017T3 (es) * 2018-12-21 2023-10-26 Sapreme Tech Bv Conjugado de anticuerpo-oligonucleótido mejorado
JP7252582B2 (ja) * 2019-01-23 2023-04-05 アブティス・カンパニー・リミテッド 抗体－ペイロードコンジュゲートの調製のための化合物及びその使用
EP4081539A4 (de) * 2019-12-24 2024-02-21 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Neuartige anti-semg2-antikörper
CN114901692A (zh) * 2019-12-24 2022-08-12 迪哲(江苏)医药股份有限公司 新颖抗fgfr2b抗体
CN115368278B (zh) * 2022-10-25 2023-04-11 北京鑫开元医药科技有限公司 一种苯磺酰胺类化合物水解制备苯磺酸类化合物的方法
CN116239513B (zh) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088172A2 (en) * 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2005081711A2 (en) * 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2007008603A1 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2009117531A1 (en) * 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2012143495A2 (de) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0553244B8 (de) 1990-10-05 2005-06-08 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
DK0511011T3 (da) 1991-04-26 1997-03-10 Surface Active Ltd Nye antistoffer og fremgangsmåde til anvendelse heraf
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
MXPA01011502A (es) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas.
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
EP2046384A4 (de) 2006-06-15 2009-12-02 Fibron Ltd Antikörper zur blockierung der fibroblasten-wachstumsfaktor-rezeptor-aktivierung und anwendungsverfahren dafür
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
PL2842573T3 (pl) 2008-11-07 2018-04-30 Galaxy Biotech, Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
ES2528956T3 (es) * 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088172A2 (en) * 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2005081711A2 (en) * 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2007008603A1 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2009117531A1 (en) * 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2012143495A2 (de) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172937B2 (en) 2013-08-01 2019-01-08 Five Prime Therapeutics, Inc. Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies
US11235059B2 (en) 2013-08-01 2022-02-01 Five Prime Therapeutics, Inc. Afucosylated anti-FGFR2IIIB antibodies
US11447553B2 (en) 2015-11-23 2022-09-20 Five Prime Therapeutics, Inc. FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US11091555B2 (en) 2017-05-16 2021-08-17 Five Prime Therapeutics, Inc. Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy

Also Published As

Publication number Publication date
RU2014128467A (ru) 2016-02-10
JP2015505850A (ja) 2015-02-26
US20150023989A1 (en) 2015-01-22
BR112014014763A8 (pt) 2017-07-04
AU2012351685A1 (en) 2014-07-03
ZA201405003B (en) 2016-01-27
SG11201403085PA (en) 2014-10-30
HK1200714A1 (en) 2015-08-14
WO2013087716A2 (de) 2013-06-20
KR20140114826A (ko) 2014-09-29
IL233050A0 (en) 2014-07-31
BR112014014763A2 (pt) 2017-06-13
CA2859255A1 (en) 2013-06-20
AR089252A1 (es) 2014-08-06
EP2790731A2 (de) 2014-10-22
MX2014007121A (es) 2014-09-04
NZ625745A (en) 2016-07-29
CN104254342A (zh) 2014-12-31

Similar Documents

Publication Publication Date Title
WO2013087716A3 (de) Fgfr- binder -wirkstoff konjugate und ihre verwendung
WO2012143497A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
EP2054416B8 (de) Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
MX380273B (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
WO2012019427A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2012051344A3 (en) Maintaining multiple defined physiological zones using model predictive control
UY30931A1 (es) Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
IL207110A0 (en) Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
HK1198869A1 (en) Combination treatments for hepatitis c
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
IL226386A0 (en) Medical treatment for metabolic syndrome, type 2 diabetes, obesity or pre-diabetes
WO2007144169A3 (de) Entacapone-derivatives
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
WO2012099899A3 (en) Topical dermatological compositions for the treatment of acne
EP2730585A4 (de) Protein-polypeptid-komplex mit spezifischer wirkung auf das hautgewebe, verfahren zur herstellung dieses komplexes und pharmazeutische zusammensetzung daraus
WO2014043336A3 (en) Tetrandrine pharmaceutical formulations and method
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
WO2012116151A3 (en) Vinyl -aryl - sulfones for use in peritoneal carcinomatosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12808324

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 233050

Country of ref document: IL

Ref document number: 14364203

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014546496

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2859255

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/007121

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2012351685

Country of ref document: AU

Date of ref document: 20121212

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147019085

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012808324

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014128467

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014014763

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014014763

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140616